Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazonium Sulfate in Pediatric Invasive Aspergillosis or Mucormycosis
NCT03816176Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of isavuconazonium in invasive aspergillosis (IA) and mucormycosis, sponsored by Astellas Pharma. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Percentage of Participants With All-Cause Mortality at Day 42. Started Aug 2019; status: completed.
02
Drugs
isavuconazonium
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT03816176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816176.